-
Something wrong with this record ?
Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer's Disease Therapy
R. Malek, B. Refouvelet, M. Benchekroun, I. Iriepa, I. Moraleda, R. Andrys, K. Musilek, J. Marco-Contelles, L. Ismaili,
Language English Country United Arab Emirates
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acetylcholinesterase metabolism MeSH
- Alzheimer Disease drug therapy metabolism MeSH
- Butyrylcholinesterase metabolism MeSH
- Cholinesterase Inhibitors chemical synthesis pharmacology MeSH
- Chromones chemical synthesis pharmacology MeSH
- Donepezil chemical synthesis pharmacology MeSH
- Humans MeSH
- Drug Evaluation, Preclinical MeSH
- Free Radical Scavengers chemical synthesis pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Many factors are involved in Alzheimer's Disease (AD) such as amyloid plaques, neurofibrillary tangles, cholinergic deficit and oxidative stress. To counter the complexity of the disease the new approach for drug development is to create a single molecule able to act simultaneously on different targets. OBJECTIVE: We conceived eight drug likeliness compounds targeting the inhibition of cholinesterases and the scavenging of radicals. METHODS: We synthesised the new molecules by the Passerini multicomponent reaction and evaluated their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) as well as their antioxidant activities by the Oxygen Radical Absorbance Capacity (ORAC) assay. The lipinski's rule for drug likeness and in silico ADME prediction was also performed. RESULTS: Compounds 4f [IC50 (EeAChE) = 0.30 μM; IC50 (eqBuChE) = 0.09 μM; ORAC = 0.64 TE] and 4h [IC50 (EeAChE) = 1 μM; IC50 (eqBuChE) = 0.03 μM; ORAC = 0.50 TE] were identified as hits for further development. CONCLUSION: The Passerini reaction allowed us the facile synthesis of ditarget molecules of interest for the treatment of AD.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025970
- 003
- CZ-PrNML
- 005
- 20201222160453.0
- 007
- ta
- 008
- 201125s2019 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1567205016666191011112624 $2 doi
- 035 __
- $a (PubMed)31660831
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Malek, Rim $u Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France.
- 245 10
- $a Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer's Disease Therapy / $c R. Malek, B. Refouvelet, M. Benchekroun, I. Iriepa, I. Moraleda, R. Andrys, K. Musilek, J. Marco-Contelles, L. Ismaili,
- 520 9_
- $a BACKGROUND: Many factors are involved in Alzheimer's Disease (AD) such as amyloid plaques, neurofibrillary tangles, cholinergic deficit and oxidative stress. To counter the complexity of the disease the new approach for drug development is to create a single molecule able to act simultaneously on different targets. OBJECTIVE: We conceived eight drug likeliness compounds targeting the inhibition of cholinesterases and the scavenging of radicals. METHODS: We synthesised the new molecules by the Passerini multicomponent reaction and evaluated their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) as well as their antioxidant activities by the Oxygen Radical Absorbance Capacity (ORAC) assay. The lipinski's rule for drug likeness and in silico ADME prediction was also performed. RESULTS: Compounds 4f [IC50 (EeAChE) = 0.30 μM; IC50 (eqBuChE) = 0.09 μM; ORAC = 0.64 TE] and 4h [IC50 (EeAChE) = 1 μM; IC50 (eqBuChE) = 0.03 μM; ORAC = 0.50 TE] were identified as hits for further development. CONCLUSION: The Passerini reaction allowed us the facile synthesis of ditarget molecules of interest for the treatment of AD.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
- 650 _2
- $a butyrylcholinesterasa $x metabolismus $7 D002091
- 650 _2
- $a cholinesterasové inhibitory $x chemická syntéza $x farmakologie $7 D002800
- 650 _2
- $a chromony $x chemická syntéza $x farmakologie $7 D002867
- 650 _2
- $a donepezil $x chemická syntéza $x farmakologie $7 D000077265
- 650 _2
- $a preklinické hodnocení léčiv $7 D004353
- 650 _2
- $a scavengery volných radikálů $x chemická syntéza $x farmakologie $7 D016166
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Refouvelet, Bernard $u Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France.
- 700 1_
- $a Benchekroun, Mohamed $u Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France.
- 700 1_
- $a Iriepa, Isabel $u Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain. Instituto de Investigación Química Andrés M. del Río (IQAR), Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain.
- 700 1_
- $a Moraleda, Ignacio $u Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain.
- 700 1_
- $a Andrys, Rudolf $u University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, Hradec Kralove, Czech Republic.
- 700 1_
- $a Musilek, Kamil $u University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, Hradec Kralove, Czech Republic.
- 700 1_
- $a Marco-Contelles, José $u Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva 3; 28006-Madrid, Spain.
- 700 1_
- $a Ismaili, Lhassane $u Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France.
- 773 0_
- $w MED00008816 $t Current Alzheimer research $x 1875-5828 $g Roč. 16, č. 9 (2019), s. 815-820
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31660831 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160448 $b ABA008
- 999 __
- $a ok $b bmc $g 1600115 $s 1116656
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 16 $c 9 $d 815-820 $e - $i 1875-5828 $m Current Alzheimer research $n Curr Alzheimer Res $x MED00008816
- LZP __
- $a Pubmed-20201125
